IB-T101 injection for advanced kidney cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests an experimental injection called IB-T101 for people with advanced clear cell renal cell carcinoma, a type of kidney cancer. It aims to see if the treatment is safe and possibly effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced clear cell renal cell carcinoma and are willing to try an experimental treatment.
- You are able to care for yourself (ECOG score 0 or 1).
- Your doctor expects you to live at least 3 more months.
- You do not have certain serious brain or nervous system conditions.
- You have not had a heart attack or unstable chest pain in the last 6 months.
- You do not have a serious immune system problem or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational medicine called HS-IT101 for people with advanced kidney cancer that hasn't responded to standard treatments. The goal is to see if this new therapy can help shrink or control the cancer.
This trial tests an experimental cell therapy (HS-IT101) for people with advanced solid tumors that have not responded to standard treatments. It uses immune cells from your own tumor to fight cancer, and researchers want to see if it is safe and effective.
This Phase 1 trial tests GT101, an injection made from your own tumor-fighting immune cells, for advanced solid cancers that can’t be removed with surgery. It’s mainly aimed at checking safety and early signs of whether the treatment may work.
This early-phase study tests GI-101 in people with advanced solid cancers. It may be given alone or combined with pembrolizumab or lenvatinib to see how safe it is and whether it can shrink tumors.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests a new drug (JS004) combined with an existing immunotherapy (toripalimab) for kidney cancer that has progressed after previous immunotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Hear when a new Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.